Biologic facts
BrandCimzia (Certolizumab Pegol)
No biosimilar to Cimzia is licensed. The 12-year reference exclusivity date of 04/2020 is an estimate from first approval; the Purple Book does not list patents, which can protect a biologic longer.
Cimzia was first approved by the FDA in 2008; the application holder is Ucb, Inc.
The latest NADAC for CIMZIA 2X200 MG/ML SYRINGE KIT is $6,098.04 per unit (as of 10/28/2026).
Holder Ucb, Inc.Approved 2008
01Exclusivity
When biosimilar competition can legally begin. The Purple Book lists reference exclusivity but not patents, which can protect a biologic longer.
- Patents
- Not listed in the Purple Book Purple Book
- Reference exclusivity
- 04/202012-year estimate from first approval Purple Book
02Competition
- Biosimilars
- No biosimilar approved Purple Book
Every makerEach licensed product and biosimilar maker.
PrescribersWho prescribes it, from Medicare data.
Spend and safetyMedicare Part B spend and safety reports.
Available in the full Cimzia profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $6,098.04 per unitCIMZIA 2X200 MG/ML SYRINGE KIT, as of 10/28/2026 CMS NADAC
- Latest recall
- 05/08/2026Class II, Certolizumab Pegol, Ucb Biosciences Inc. FDA enforcement
04Product
- Application holder
- Ucb, Inc. Purple Book
- First approved
- 2008 Purple Book
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.